Genetic profiling of basal cell carcinomas detects postzygotic mosaicism in basal cell naevus syndrome.
Journal
The British journal of dermatology
ISSN: 1365-2133
Titre abrégé: Br J Dermatol
Pays: England
ID NLM: 0004041
Informations de publication
Date de publication:
09 2019
09 2019
Historique:
accepted:
14
10
2018
pubmed:
7
12
2018
medline:
3
10
2020
entrez:
7
12
2018
Statut:
ppublish
Résumé
Basal cell naevus syndrome (BCNS) is associated with germline mutations in the PTCH1 gene. Postzygotic mosaicism can also cause BCNS. Here we describe two patients, one with multiple basal cell carcinomas (BCCs) and one with clinical BCNS, who had no PTCH1 mutation in DNA extracted from blood. In both patients, we performed genetic analysis on different BCCs, revealing the presence of a shared PTCH1 mutation in all tumours. Our findings show that in patients with symptoms of BCNS and initial absence of a PTCH1 mutation in blood, genetic profiling of BCCs can detect postzygotic mosaicism. What's already known about this topic? Basal cell naevus syndrome (BCNS) is associated with germline mutations in the PTCH1 gene, but it can also be caused by low-grade postzygotic mosaicism in PTCH1. What does this study add? In patients suspected of having BCNS or patients with multiple basal cell carcinomas (BCCs) with a special distribution on the body and no mutation detected in blood, it is worthwhile to search for a shared PTCH1 mutation in their BCCs as this can detect postzygotic mosaicism. This information is important to ensure proper surveillance programmes, choose the right therapy and provide adequate genetic counselling.
Substances chimiques
PTCH1 protein, human
0
Patched-1 Receptor
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
587-591Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2018 British Association of Dermatologists.
Références
John AM, Schwartz RA. Basal cell naevus syndrome: an update on genetics and treatment. Br J Dermatol 2016; 174:68-76.
Bree AF, Shah MR. Consensus statement from the first international colloquium on basal cell nevus syndrome (BCNS). Am J Med Genet A 2011; 155A:2091-7.
Camisa C, Rossana C, Little L. Naevoid basal-cell carcinoma syndrome with unilateral neoplasms and pits. Br J Dermatol 1985; 113:365-7.
Gutierrez MM, Mora RG. Nevoid basal cell carcinoma syndrome. A review and case report of a patient with unilateral basal cell nevus syndrome. J Am Acad Dermatol 1986; 15:1023-30.
Shelley WB, Rawnsley HM, Beerman H. Quadrant distribution of basal cell nevi. Arch Dermatol 1969; 100:741-3.
Reinders MG, Boersma HJ, Leter EM et al. Postzygotic mosaicism in basal cell naevus syndrome. Br J Dermatol 2017; 177:249-52.
Khamaysi Z, Bochner R, Indelman M et al. Segmental basal cell naevus syndrome caused by an activating mutation in smoothened. Br J Dermatol 2016; 175:178-81.
Happle R, Tinschert S. Happle-Tinschert syndrome can be caused by a mosaic SMO mutation and is suggested to be a variant of Curry-Jones syndrome. Br J Dermatol 2016; 175:1108.
Zenker M, Tinschert S, Wieland I et al. A postzygotic SMO mutation caused the original case of Happle-Tinschert syndrome. Acta Derm Venereol 2018; 98:534-5.
Torrelo A, Hernández-Martín A, Bueno E et al. Molecular evidence of type 2 mosaicism in Gorlin syndrome. Br J Dermatol 2013; 169:1342-5.
Toberer F, Happle R, Schneiderbauer R et al. At first sight or second glance: clinical presentation of mosaic manifestations of autosomal dominant skin disorders - a case series. J Eur Acad Dermatol Venereol 2017; 31:1912-15.
Happle R. Mosaicism in Human Skin: Understanding Nevi, Nevoid Skin Disorders, and Cutaneous Neoplasia. Berlin: Springer, 2014.